Immunicum to present at the Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting November 11 - 13

Gothenburg, Sweden, September 19, 2016. Immunicum AB (publ), a biopharmaceutical company pursuing to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced that it will present data from its INTUVAX – HCC I/II clinical study at the Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting.

SITC has accepted Immunicum’s poster containing clinical data from INTUVAX – HCC I/II for presentation at the SITC 31st Annual Meeting, to be held November 11-13, 2016 in National Harbor, Maryland, USA. Alex Karlsson-Parra, Immunicum’s Chief Scientific Officer, will present the poster titled “Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers – a phase I/II study in patients with advanced hepatocellular carcinoma”.

– SITC’s acceptance is yet another prestigious marker of the scientific interest in INTUVAX and our clinical data. We also plan to give our next clinical data update on the HCC study in connection to the SITC meeting, says Jamal El-Mosleh, CEO of Immunicum.

For more information, please contact:
Jamal El-Mosleh, CEO, Immunicum
Ph: +46 (0) 31 41 50 52

About Immunicum AB (publ)
Immunicum AB (publ) develops cancer immune primers for the treatment of
tumor diseases. A phase II clinical trial for the Company’s most advanced
product – INTUVAX® against kidney cancer – has been initiated. The project
portfolio contains additional clinical phase I/II studies in liver cancer and in
gastrointestinal stromal tumors (GIST). Immunicum is listed on First North Premier.

The company’s Certified Adviser is Redeye AB
Ph: + 46 8 545 013 31

The information in this press release is disclosed pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the agency of the company’s contact person on September 19, 2016 at 08.45 CET

Keep reading

Immunicum presents continued improvement in phase I/II survival data for INTUVAX-treated renal cancer patients